Cargando…
SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy
Immunotherapy treatment with checkpoint inhibitors (CPI) (CTLA-4 and PD-1 inhibitors) significantly improves survival in a number of cancers. Treatment can be limited by immune-mediated adverse effects including endocrinopathies such as hypophysitis, adrenalitis, thyroiditis and diabetes mellitus. I...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013692/ https://www.ncbi.nlm.nih.gov/pubmed/29930025 http://dx.doi.org/10.1530/EC-18-0068 |
_version_ | 1783334064086843392 |
---|---|
author | Higham, C E Olsson-Brown, A Carroll, P Cooksley, T Larkin, J Lorigan, P Morganstein, D Trainer, P J |
author_facet | Higham, C E Olsson-Brown, A Carroll, P Cooksley, T Larkin, J Lorigan, P Morganstein, D Trainer, P J |
author_sort | Higham, C E |
collection | PubMed |
description | Immunotherapy treatment with checkpoint inhibitors (CPI) (CTLA-4 and PD-1 inhibitors) significantly improves survival in a number of cancers. Treatment can be limited by immune-mediated adverse effects including endocrinopathies such as hypophysitis, adrenalitis, thyroiditis and diabetes mellitus. If endocrinopathies (particularly hypocortisolemia) are not recognized early, they can be fatal. The diagnosis and management of endocrinopathies can be complicated by simultaneous multi-organ immune adverse effects. Here, we present Endocrine Emergency Guidance for the acute management of the endocrine complications of checkpoint inhibitor therapy, the first specialty-specific guidance with Endocrinology, Oncology and Acute Medicine input and endorsed by the Society for Endocrinology Clinical Committee. We present algorithms for management: endocrine assessment and management of patients in the first 24 hours who present life-threateningly unwell (CTCAE grade 3–4) and the appropriate management of mild-moderately unwell patients (CTCAE grade 1–2) presenting with features compatible with an endocrinopathy. Other important considerations in relation to hypohysitis and the maintenance of glucocorticoid therapy are discussed. |
format | Online Article Text |
id | pubmed-6013692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-60136922018-06-26 SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy Higham, C E Olsson-Brown, A Carroll, P Cooksley, T Larkin, J Lorigan, P Morganstein, D Trainer, P J Endocr Connect Guidelines and Guidance Immunotherapy treatment with checkpoint inhibitors (CPI) (CTLA-4 and PD-1 inhibitors) significantly improves survival in a number of cancers. Treatment can be limited by immune-mediated adverse effects including endocrinopathies such as hypophysitis, adrenalitis, thyroiditis and diabetes mellitus. If endocrinopathies (particularly hypocortisolemia) are not recognized early, they can be fatal. The diagnosis and management of endocrinopathies can be complicated by simultaneous multi-organ immune adverse effects. Here, we present Endocrine Emergency Guidance for the acute management of the endocrine complications of checkpoint inhibitor therapy, the first specialty-specific guidance with Endocrinology, Oncology and Acute Medicine input and endorsed by the Society for Endocrinology Clinical Committee. We present algorithms for management: endocrine assessment and management of patients in the first 24 hours who present life-threateningly unwell (CTCAE grade 3–4) and the appropriate management of mild-moderately unwell patients (CTCAE grade 1–2) presenting with features compatible with an endocrinopathy. Other important considerations in relation to hypohysitis and the maintenance of glucocorticoid therapy are discussed. Bioscientifica Ltd 2018-03-27 /pmc/articles/PMC6013692/ /pubmed/29930025 http://dx.doi.org/10.1530/EC-18-0068 Text en © 2018 Society for Endocrinology http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Guidelines and Guidance Higham, C E Olsson-Brown, A Carroll, P Cooksley, T Larkin, J Lorigan, P Morganstein, D Trainer, P J SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy |
title | SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy |
title_full | SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy |
title_fullStr | SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy |
title_full_unstemmed | SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy |
title_short | SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy |
title_sort | society for endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy |
topic | Guidelines and Guidance |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013692/ https://www.ncbi.nlm.nih.gov/pubmed/29930025 http://dx.doi.org/10.1530/EC-18-0068 |
work_keys_str_mv | AT highamce societyforendocrinologyendocrineemergencyguidanceacutemanagementoftheendocrinecomplicationsofcheckpointinhibitortherapy AT olssonbrowna societyforendocrinologyendocrineemergencyguidanceacutemanagementoftheendocrinecomplicationsofcheckpointinhibitortherapy AT carrollp societyforendocrinologyendocrineemergencyguidanceacutemanagementoftheendocrinecomplicationsofcheckpointinhibitortherapy AT cooksleyt societyforendocrinologyendocrineemergencyguidanceacutemanagementoftheendocrinecomplicationsofcheckpointinhibitortherapy AT larkinj societyforendocrinologyendocrineemergencyguidanceacutemanagementoftheendocrinecomplicationsofcheckpointinhibitortherapy AT loriganp societyforendocrinologyendocrineemergencyguidanceacutemanagementoftheendocrinecomplicationsofcheckpointinhibitortherapy AT morgansteind societyforendocrinologyendocrineemergencyguidanceacutemanagementoftheendocrinecomplicationsofcheckpointinhibitortherapy AT trainerpj societyforendocrinologyendocrineemergencyguidanceacutemanagementoftheendocrinecomplicationsofcheckpointinhibitortherapy AT societyforendocrinologyendocrineemergencyguidanceacutemanagementoftheendocrinecomplicationsofcheckpointinhibitortherapy |